Med-tech trends: The most talked about device makers in January 2013

February 5, 2013 by MassDevice staff

Click to enlarge.

MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.

Medical device titan Medtronic (NYSE:MDT) remained the Google search champion for another month, releasing a slate of news regarding regulatory wins and clinical trials, as well as providing updates on the road ahead with a MassDevice.com interview following the company's earnings report.

Sign up to get our free newsletters delivered right to your inbox.

Johnson & Johnson (NYSE:JNJ) followed behind, making headlines with news of the high-profile legal battles over its metal-on-metal hips and transvaginal mesh implants. Boston Scientific (NYSE:BSX) hit a new 52-week-highs twice during the month after new CEO Michael Mahoney delivered a presentation at the J.P. Morgan conference in California.

St. Jude Medical (NYSE:STJ) and GE Healthcare's (NYSE:GE) rounded out the top 5 with news of FDA warnings, European regulatory wins and 4th-quarter earnings reports.

Medtronic

• Alisanos slaps Medtronic with patent suit over Octopus Evolution - January 7
• Medtronic narrows 2013 guidance - January 7
• Interview: Medtronic CEO Ishrak on the road ahead - January 8
• Medtronic asks court to strike insulin pump fraud case - January 9
• Diabetes: GI Dynamics inks research deals with Medtronic, GlaxoSmithKline - January 9
• Medtronic can't dodge pain pump lawsuit - January 11
• Medtronic touts FDA win, commercial launch of next-gen FlexCath sheath - January 16
• Medtronic announces 1st implant in Reveal trial - January 18
• Medtronic lands new EU indications for Complete SE stent - January 24
• Medtronic closes enrollment in drug-eluting balloon study - January 28
• Back pain: Medtronic launches global spinal cord neurostim trial - January 28
• Medtronic closes strategic investment in LifeTech - January 30
• Medtronic's neurostim implants safe with full-body MRI, EU regulators say - January 30

Johnson & Johnson

• Legal fights over recalled hips and transvaginal mesh begin this year - January 2
• Juror selection begins for Johnson & Johnson transvaginal mesh lawsuits - January 15
• Johnson & Johnson looks to reboot medical device business - January 22
• Cordis unveils 2-year trial results for S.M.A.R.T. vascular stent systems - January 22
• Diabetes: Certain J&J insulin pumps destined to fail over software issue - January 22
• 1 in 3 metal hips may fail in under 5 years, J&J analysis finds - January 23
• J&J dodged years of warnings before recalling metal hips, lawsuit claims - January 29

Boston Scientific

• Hauser curbs enthusiasm for Boston Scientific's lead-free implanted defibrillator - January 2
• Mahoney: Too much CEO turnover at Boston Scientific - January 8
• Whistleblower asks appeals court to revive lawsuit against Boston Scientific - January 9
• Can Boston Scientific capitalize on St. Jude's challenges? - January 9
• Boston Scientific hits 52-week high on Credit Suisse nod - January 16
• Boston Scientific treats 1st patient in Zero AF trial, aims for FDA win for Blazer catheter - January 16
• Boston Scientific gains on Q4, 2012 numbers, announces more layoffs - January 29
• Boston Scientific hits 52-week high - January 31

St. Jude Medical

• St. Jude and AorTech come to terms over troubled supply deal - January 3
• St. Jude Medical cops to Durata plant problems - January 9
• St. Jude defends Durata amid FDA warning at manufacturing facility - January 10
• FDA slaps St. Jude Medical with warning letter - January 14
• St. Jude Medical seesaws on FDA warning letter - January 15
• FDA approves St. Jude's Merlin.net web-based remote cardiac monitor - January 16
• St. Jude wins EU approval for ViewFlex Xtra ICE catheter - January 17
• St. Jude lands European win for next-gen Amplatzer stroke prevention device - January 18
• St. Jude Medical's Q4, 2012 results beat Wall Street's expectations - January 23
• St. Jude eyes larger patient group in new renal denervation study - January 30

GE Healthcare

• Strong Q4 pushes GE Healthcare's 2012 profits up 4% - January 18

Permalink